HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Arformoterol

HCID 178947388
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1198353-13-7
Standard SMILES
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1
InChIKey
BPZSYCZIITTYBL-YJYMSZOUSA-N
Molecular formula
C19H24N2O4
Average molar mass
344.4 g/mol

Overview

Arformoterol is an N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide in which both of the stereocentres have R configuration. The active enantiomer of formoterol, it is administered by inhalation (generally as the tartrate salt) as a direct-acting sympathomimetic and bronchodilator for the treatment of chronic obstructive pulmonary disease (any progressive respiratory disease that makes it harder to breathe over time, such as chronic bronchitis and emphysema). It has a role as a beta-adrenergic agonist, a bronchodilator agent and an anti-asthmatic drug. It is a conjugate base of an arformoterol(1+). It is an enantiomer of a (S,S)-formoterol.

Names & identifiers

Preferred name
Arformoterol
IUPAC
N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
English name
FORMOTEROL-D3
Molecular formula
C19H24N2O4
Molecular weight
344.41

Names & synonyms

Arformoterol(R,R)-Formoterol67346-49-0(-)-FormoterolN-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamideF91H02EBWTN-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamideCHEBI:408174DTXSID40110071Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (R-(R*,R*))-arformoterolum
Show more names
FORMOTEROL-D3Arformoterol-d3(R,R)-Formoterol-d3 (Arformoterol-d3)(R,R)-Formoterol-d3 ((R,R)-Arformoterol-d3)
Formoterol r,r-Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((2R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamideRefChem:5561DTXCID203077Arformoterol [INN]AtimosArformoterol (INN)

Properties

Computed structural propertiesFilling in

XLogP
1.8
Topological polar surface area
90.8 Ų
Hydrogen bond donors
4
Hydrogen bond acceptors
5
Rotatable bonds
8
Heavy atoms
25
Formal charge
0
Complexity
388

Experimental & physicochemical properties

DrugsPharmaceutical
LogP2.2
Solubility4.16e-02 g/L
Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Beta Adrenergic Agonists; Bronchodilator Agents

Pharmaceuticals

Physical DescriptionSolid

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Chemistry & industry

Pharmacology

ATC CodeR03AC13
Protein BindingThe binding of arformoterol to human plasma proteins in vitro was 52-65% at concentrations of 0.25, 0.5 and 1.0 ng/mL of radiolabeled arformoterol.
Pharmacodynamics · 1 item

Arformoterol, the active (R,R)-enantiomer of formoterol, is a selective long-acting β2-adrenergic receptor agonist (beta2-agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent as a β2-agonist than the (R,R)-enantiomer. Arformoterol seems to have little or no effect on β1-adrenergic receptors.

Mechanism of Action · 1 item

While it is recognized that β2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and β1-receptors are the predominant receptors in the heart, data indicate that there are also β2-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective β2-agonists may have cardiac effects. The pharmacologic effects of β2-adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to the stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3,5-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of the release of proinflammatory mediators from cells, especially from mast cells. In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-response.

Biological Half-LifeIn COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
Metabolism/Metabolites

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
1198353-13-7
ChEMBL
CHEMBL1363
ChEBI
CHEBI:408174
UNII
5ZZ84GCW8B、F91H02EBWT
Nikkaji
J245.605B
· 1 item

Arformoterol was almost entirely metabolized following oral administration of 35 mcg of radiolabeled arformoterol in eight healthy subjects. Direct conjugation of arformoterol with glucuronic acid was the major metabolic pathway. O-Desmethylation is a secondary route catalyzed by the CYP enzymes CYP2D6 and CYP2C19.

FDA Pharmacological Classification · 5 items

F91H02EBWT

ARFORMOTEROL

Mechanisms of Action [MoA] - Adrenergic beta2-Agonists

Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist

Arformoterol is a beta2-Adrenergic Agonist. The mechanism of action of arformoterol is as an Adrenergic beta2-Agonist.

MeSH Pharmacological Classification · 2 items

Agents that cause an increase in the expansion of a bronchus or bronchial tubes.

Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.

Absorption, Distribution and Excretion · 3 items

In patients with COPD, the mean peak plasma concentration (Cmax) and AUC0-12h following twice daily administration for 14 days were 4.3 pg/mL and 34.5 pg.hr/mL, respectively. The time to peak plasma concentration (Tmax) was approximately 0.5 hours.

Following the administration of a single oral dose of arformoterol to eight healthy subjects, 63% of the administered dose was recovered in the urine and 11% in the feces within 48 hours. After 14 days, a total of 89% of the total dose had been recovered - 67% in the urine and 22% in the feces - with approximately 1% remaining unchanged in the urine.

In healthy male subjects, the clearance of a single oral dose of arformoterol was 8.9 L/h.

Cellular LocationsMembrane

Uses & manufacturing

Use ClassificationPharmaceuticals
Applications · 1 item

UsesFormoterol-d3 is deuterium labeled Arformoterol. Arformoterol ((R,R)-Formoterol), the (R,R)-enantiomer of Formoterol, is a long-acting β2-adrenergic receptor (β2-AR) agonist, with a Kd of 2.9 nM. Arformoterol can be used for the research of chronic obstructive pulmonary disease (COPD)[1][2].